Signal transduction defects in growth hormone insensitivity

Acta Paediatrica, International Journal of Paediatrics, Supplement

Volumn 88, Issue 428, 1999, Pages 174-178

  Clayton, P E ^a   Freeth, J S ^a   Whatmore, A J ^a   Ayling, R M ^b   Norman, M R ^c   Silva, C M ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Growth hormone insensitivity; Growth hormone receptor; Laron syndrome; Mitogen activated protein kinase; Signal transducers and activators of transcription

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE;

AUTOSOMAL RECESSIVE INHERITANCE; CLINICAL ARTICLE; CONFERENCE PAPER; GENE MUTATION; HORMONE RESISTANCE; HUMAN; IMMUNOBLOTTING; LARON SYNDROME; PATHOPHYSIOLOGY; PEDIGREE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR GENE; SHORT STATURE; SIGNAL TRANSDUCTION;

EID: 0033017783     PISSN: 08035326     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone: a new inborn error of metabolism? Isr J Med Sci 1966;2:152-5
2. Eshet R, Laron Z, Pertzelan A, Arnon R, Dintzman M. Defect of human growth hormone receptors in the liver of two patients with Laron-type dwarfism. Isr J Med Sci 1984;20:8-11
3. Amselem S, Duquesnoy P, Attree O, Novelli G, Bousnina S, Postel-Vinay M-C, et al. Laron dwarfism and mutations of the growth hormone-receptor gene. N Engl J Med 1989;321:989-95
4. Buchanan CR, Maheshwari HG, Norman MR, Morrell DJ, Preece MA. Laron-type dwarfism with apparently normal high affinity serum growth hormone binding protein. Clin Endocrinol 1991;35:179-85
5. Woods KA, Dastot F, Preece MA, Clark AJL, Postel-Vinay M-C, Chatelain PG, et al. Phenotype.-genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab 1997;82:3529-35
6. Duquesnoy P, Sobrier M-L, Duriez B, Dastot F, Buchanan CR, Savage MO, et al. A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron syndrome) with positive GH-binding activity by abolishing receptor homodimerisation. EMBO J 1994;13:1386-95
7. Esposito N, Wojcik J, Chomilier J, Martini JF, Kelly PA, Finidori J, et al. The D152H mutation found in growth hormone insensitivity syndrome impairs expression and function of human growth hormone receptor but is silent in rat receptors. J Mol Endocrinol 1998;21(1):61-72
8. Woods KA, Fraser NC, Postel-Vinay M-C, Savage MO, Clark AJL. A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein. J Clin Endocrinol Metab 1996;81:1686-90
9. Silbergeld A, Dastot F, Klinger B, Kanety H, Eshet R, Amselem S, et al. Intronic mutation in the growth hormone (GH) receptor gene from a girl with Laron syndrome and extremely high serum GH binding protein: extended phenotypic study in a very large pedigree. J Pediatr Endocrinol Metab 1997;10:265-74
10. Ayling RM, Ross R, Towner P, Von Laue S, Finidori J, Moutoussamy S, et al. A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat Genet 1997;16:13-14
11. Ross RJM, Esposito N, Shen XY, Von Laue S, Chew SL, Dobson PRM, et al. A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein. Mol Endocrinol 1997;11:265-73
12. Iida K, Takahashi Y, Kaji H, Nose O, Okimura Y, Abe H, et al. Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain. J Clin Endocrinol Metab 1998;83:531-7
13. Laron Z, Klinger B, Eshet R, Kanety H, Karasik A, Silbergeld A. Laron syndrome due to a post-receptor defect: response to IGF-I treatment. Isr J Med Sci 1993;29:757-63
14. Freeth JS, Ayling RM, Whatmore AJ, Towner P, Price DA, Norman MR, et al. Human skin fibroblasts as a model of growth hormone (GH) action in GH receptor-positive Laron's syndrome. Endocrinology 1997;138:55-61
15. Freeth JS, Silva CM, Whatmore AJ, Clayton PE. Activation of the signal transducers and activators of transcription signalling pathway by growth hormone (GH) in skin fibroblasts from normal, and GH binding protein-positive Laron syndrome children. Endocrinology 1998;139:20-8
16. Love DW, Whatmore AJ, Clayton PE, Silva CM. Growth hormone stimulation of the MAP kinase pathway is cell type specific. Endocrinology 1998;139:1965-71
17. Whatmore AJ, Silva CM, Freeth JS, Clayton PE. Growth hormone (GH) signal transduction in cultured fibroblasts from normal and GH binding protein (GHBP)-positive Laron children. Proceedings of the 10th International Congress of Endocrinology, San Francisco, 1996:OR7-8
18. s6k pathways. Biochem J 1996;315:517-22